Molecular targeted therapies for patients with refractory thyroid cancer.
The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.
Chougnet
C
C
Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence Tumeurs Réfractaires de la Thyroïde, Institut Gustave Roussy and University Paris-Sud XI, Villejuif, France.
Brassard
M
M
Leboulleux
S
S
Baudin
E
E
Schlumberger
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors